886767-25-5

Basic information

• Product Name: tert-butyl 3-(4-fluorophenyl)piperazine-1-carboxylate
• Synonyms: tert-butyl 3-(4-fluorophenyl)piperazine-1-carboxylate;1-BOC-3-(4-FLUOROPHENYL)PIPERAZINE;Tert-Butyl 3-(4-Fluorophenylpiperazine-1-
• CAS NO: 886767-25-5
• Molecular Formula: C₁₅H₂₁FN₂O₂
• Molecular Weight: 280.3378432
• Mol File: 886767-25-5.mol

Chemical Properties

• Boiling Point: 370.4±42.0 °C(Predicted)
• Appearance: /
• Density: 1.125±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 7?+-.0.40(Predicted)
• CAS DataBase Reference: tert-butyl 3-(4-fluorophenyl)piperazine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 3-(4-fluorophenyl)piperazine-1-carboxylate(886767-25-5)
• EPA Substance Registry System: tert-butyl 3-(4-fluorophenyl)piperazine-1-carboxylate(886767-25-5)

Safety Data

• Hazardous Substances Data: 886767-25-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
Tert-butyl 3-(4-fluorophenyl)piperazine-1-carboxylate is utilized as a chemical intermediate for the synthesis of various bioactive molecules and pharmaceutical drugs. Its unique structure allows for the development of compounds with potential therapeutic applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, tert-butyl 3-(4-fluorophenyl)piperazine-1-carboxylate is employed as a precursor in the design and synthesis of new drugs. Its versatility in chemical reactions enables the creation of a range of molecules with different pharmacological profiles.
Used in Neurological Disorders Treatment:
Tert-butyl 3-(4-fluorophenyl)piperazine-1-carboxylate is studied for its potential applications in the treatment of neurological disorders. Its pharmacological properties, such as its antipsychotic and anxiolytic effects, make it a promising candidate for further research and development in this area.
Used in Drug Development for Anxiety and Psychosis:
tert-butyl 3-(4-fluorophenyl)piperazine-1-carboxylate is considered for use as a drug development candidate for conditions such as anxiety and psychosis. Its potential as an anxiolytic and antipsychotic agent is currently under investigation, with the aim of identifying new treatment options for these mental health disorders.

Upstream product

• 1557287-99-6 tert-butyl (2-aminoethyl)((tributylstannyl)methyl)carbamate 
• 459-57-4 4-fluorobenzaldehyde 

Relevant articles and documents

ANTAGONISTS OF GPR39 PROTEIN

Novel compounds that act as antagonists to human GPR39 protein are disclosed. Pharmaceutical compositions and methods of use for antagonists to human GPR39 protein are disclosed. In particular, methods of using the antagonists in the treatment of diseases or conditions including cardiovascular conditions, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases are disclosed herein.

Iridium-catalyzed Synthesis of Saturated N-Heterocycles from Aldehydes and SnAP Reagents with Continuous Flow Photochemistry

Commercially available tin amine protocol (SnAP) reagents provide a simple approach to the synthesis of a wide variety of saturated N-heterocycles from aldehydes. In this report, we disclose that the copper(II) promoter and hexafluoroisopropanol can be replaced by photocatalytic conditions using Ir[dF(CF3)ppy]2(dtbbpy)PF6 in CH3CN. Continuous flow photochemical conditions provide a clean, scalable approach to valuable products including morpholines, piperazines, thiomorpholines, diazepanes, and oxazepanes from aldehyde starting materials.

Piperazine derivatives and the use thereof as medicament

The present inventions relate to substituted piperazine derivatives of general formula (I) and to the manufacture of said compounds, pharmaceutical compositions comprising a compound according to general formula (I), and the use of said compounds for the treatment of various medical conditions related to glycine transporter-1 (GlyT1).

PIPERAZINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT

The present inventions relate to substituted piperazine derivatives of general formula (I) and to the manufacture of said compounds, pharmaceutical compositions comprising a compound according to general formula (I), and the use of said compounds for the treatment of various medical conditions related to glycine transporter-1 (GlyT1).